Editorial
Molecular targeted therapies in non-small cell lung cancer: where we are
Translational Lung Cancer Research
2019;
8
(Suppl 3)
:S222-S223
.
(22 November 2019)
Original Article
Elemental and mutational analysis of lung tissue in lung adenocarcinoma patients
Translational Lung Cancer Research
2019;
8
(Suppl 3)
:S224-S234
.
(22 November 2019)
Review Article
Epidermal growth factor receptor first generation tyrosine-kinase inhibitors
Translational Lung Cancer Research
2019;
8
(Suppl 3)
:S235-S246
.
(22 November 2019)
Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
Translational Lung Cancer Research
2019;
8
(Suppl 3)
:S247-S264
.
(22 November 2019)
Role of liquid biopsy in oncogene-addicted non-small cell lung cancer
Translational Lung Cancer Research
2019;
8
(Suppl 3)
:S265-S279
.
(22 November 2019)
New generation anaplastic lymphoma kinase inhibitors
Translational Lung Cancer Research
2019;
8
(Suppl 3)
:S280-S289
.
(22 November 2019)
Expanding anaplastic lymphoma kinase therapeutic indication to early stage non-small cell lung cancer
Translational Lung Cancer Research
2019;
8
(Suppl 3)
:S290-S297
.
(22 November 2019)
Brain metastases in oncogene-driven non-small cell lung cancer
Translational Lung Cancer Research
2019;
8
(Suppl 3)
:S298-S307
.
(22 November 2019)
Biomarker for personalized immunotherapy
Translational Lung Cancer Research
2019;
8
(Suppl 3)
:S308-S317
.
(22 November 2019)
Editorial Commentary
Tyrosine kinase inhibitors interstitial pneumonitis: diagnosis and management
Translational Lung Cancer Research
2019;
8
(Suppl 3)
:S318-S320
.
(22 November 2019)
Disclosure:
The supplement “Targeted Therapies in NSCLC: An Evolving Landscape” was commissioned by the editorial office, Translational Lung Cancer Research without any sponsorship or funding. Lucio Crinò and Angelo Delmonte served as the unpaid Guest Editors for the supplement.
